Thus, targeting S100A14 is likely an effective strategy for preventing CRC progression, and S100A14 could be regarded as a promising indicator for anti-PD-L1 immunotherapy and chemotherapy. The gene discussed is S100A14; the disease is colorectal carcinoma.